Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

85.24USD
9:02pm BST
Change (% chg)

$-0.27 (-0.32%)
Prev Close
$85.51
Open
$85.55
Day's High
$86.26
Day's Low
$84.81
Volume
2,182,006
Avg. Vol
3,215,703
52-wk High
$86.50
52-wk Low
$59.81

Select another date:

Fri, Jun 21 2019

Photo

Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries

NEW YORK Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it Medicare program on lower prices in other countries would face legal challenges if adopted.

Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries

NEW YORK, June 20 Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it Medicare program on lower prices in other countries would face legal challenges if adopted.

Walmart, Merck in blockchain collaboration with FDA

June 13 IBM Corp, Merck & Co, KPMG and Walmart Inc said on Thursday they will be a part of U.S. Food and Drug Administration's pilot program that will explore using blockchain to identify, track and trace prescription drugs.

Merck's Keytruda wins FDA approval to treat head and neck cancer

Merck & Co Inc said on Tuesday its blockbuster cancer drug Keytruda won approval from the U.S. Food and Drug Administration to treat a type of head and neck cancer.

UPDATE 1-Merck's Keytruda wins FDA approval to treat head and neck cancer

June 11 Merck & Co Inc said on Tuesday its blockbuster cancer drug Keytruda won approval from the U.S. Food and Drug Administration to treat a type of head and neck cancer.

Merck's Keytruda wins FDA approval to treat head and neck cancer

June 11 Merck & Co Inc said on Tuesday its blockbuster cancer drug Keytruda won approval from the U.S. Food and Drug Administration to treat a type of head and neck cancer.

Merck to buy Tilos Therapeutics for up to $773 million

Drugmaker Merck & Co Inc said on Monday it agreed to buy privately held Tilos Therapeutics for up to $773 million, bolstering its pipeline of drugs to treat cancer and autoimmune diseases.

Merck to buy Tilos Therapeutics for up to $773 mln

June 10 Drugmaker Merck & Co Inc said on Monday it agreed to buy privately held Tilos Therapeutics for up to $773 million, bolstering its pipeline of drugs to treat cancer and autoimmune diseases.

Merck wins U.S. FDA approval for expanded use of antibiotic

The U.S. Food and Drug Administration said https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hospital-acquired-and-ventilator-associated-bacterial-pneumonia on Monday it approved expanded use of Merck & Co Inc's antibiotic to treat hospital-acquired pneumonia in patients 18 years and older.

UPDATE 1-Merck wins U.S. FDA approval for expanded use of antibiotic

June 3 The U.S. Food and Drug Administration said https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hospital-acquired-and-ventilator-associated-bacterial-pneumonia on Monday it approved expanded use of Merck & Co Inc's antibiotic to treat hospital-acquired pneumonia in patients 18 years and older.

Select another date: